6160.HK
Price:
$154.4
Market Cap:
$31.58B
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Industry
Medical - Pharmaceuticals
IPO Date
2018-08-08
Stock Exchange
HKSE
Ticker
6160.HK
According to BeiGene, Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 1.96. This represents a change of 2.33% compared to the average of 1.92 of the last 4 quarters.
The mean historical Current Ratio of BeiGene, Ltd. over the last ten years is 4.88. The current 1.96 Current Ratio has changed 3.92% with respect to the historical average. Over the past ten years (40 quarters), 6160.HK's Current Ratio was at its highest in in the March 2016 quarter at 15.91. The Current Ratio was at its lowest in in the December 2024 quarter at 1.80.
Average
4.88
Median
4.36
Minimum
1.80
Maximum
10.68
Discovering the peaks and valleys of BeiGene, Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 253.46%
Maximum Annual Current Ratio = 10.68
Minimum Annual Increase = -48.02%
Minimum Annual Current Ratio = 1.80
Year | Current Ratio | Change |
---|---|---|
2024 | 1.80 | -22.39% |
2023 | 2.32 | -34.51% |
2022 | 3.55 | -25.51% |
2021 | 4.76 | 3.17% |
2020 | 4.61 | 12.54% |
2019 | 4.10 | -48.02% |
2018 | 7.89 | 29.50% |
2017 | 6.09 | -42.97% |
2016 | 10.68 | 253.46% |
2015 | 3.02 | -14.39% |
The current Current Ratio of BeiGene, Ltd. (6160.HK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.56
5-year avg
3.41
10-year avg
4.88
BeiGene, Ltd.’s Current Ratio is less than Innovent Biologics, Inc. (2.35), less than WuXi AppTec Co., Ltd. (2.29), greater than Shanghai Junshi Biosciences Co., Ltd. (1.40), less than WuXi Biologics (Cayman) Inc. (2.73), less than Akeso, Inc. (5.15),
Company | Current Ratio | Market cap |
---|---|---|
2.35 | $130.06B | |
2.29 | $201.53B | |
1.40 | $31.63B | |
2.73 | $100.70B | |
5.15 | $84.62B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeiGene, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BeiGene, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is BeiGene, Ltd.'s Current Ratio?
How is the Current Ratio calculated for BeiGene, Ltd. (6160.HK)?
What is the highest Current Ratio for BeiGene, Ltd. (6160.HK)?
What is the 3-year average Current Ratio for BeiGene, Ltd. (6160.HK)?
What is the 5-year average Current Ratio for BeiGene, Ltd. (6160.HK)?
How does the current Current Ratio for BeiGene, Ltd. (6160.HK) compare to its historical average?